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-0.67% point (p < 0.001) for repaglinide plus metformin
and nateglinide plus metformin, respectively. Incremental
cost-effectiveness showed that the repaglinide plus met-
formin combination was a superior healthcare strategy.
The difference in QALY was 0.26 years (LYG was 0.40
years) and lifetime cost was lower, due to fewer compli-
cations. Furthermore, clinical outcomes showed that the
largest contributor to lifetime costs was cardiovascular
events (37%), followed by cost for drugs (31%), neu-
ropathy (25%), retinopathy (5%) and nephropathy (2%).
Sensitivity analyses support the validity and reliability of
the results. CONCLUSIONS: The improved efﬁcacy rate
in the repaglinide plus metformin group was estimated 
to be a cost-effective way of treating Type 2 diabetes, as
compared to a regimen of nateglinide plus metformin.
Further outcomes studies are needed to support these
ﬁndings.
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OBJECTIVE: To determine the long-term clinical and
economic outcomes of combined ACE-inhibitor and
calcium antagonist therapy (Tarka) versus standard care
for preventing the development of end-stage renal disease
in type 2 diabetic patients with hypertension and macro-
proteinuria in the United States. METHODS: Markov
process analysis techniques were used to model the health
economic outcomes. Probabilities, unit costs, resource
utilization data and utilities were obtained from pub-
lished literature, clinical trial reports, and a national data-
base (USRDS). Progression of renal failure was measured
using the rate of proteinuria as indicator. The perspective
was that of the third-party payer. RESULTS: In the 5-year
analysis Tarka yielded a 0.1 gain in QALYs when it was
compared to ACE-inhibitor (4.1 versus 4.0) and 0.2 gains
in QALYs compared to calcium antagonist (4.1 vs. 3.9).
The lifetime model yielded a gain of 0.7 QALYs when it
was compared to ACE-inhibitor (7.6 vs. 6.9) and a gain
of 0.8 QALYs compared to calcium antagonist (7.6 vs.
6.8). In the lifetime analysis Tarka resulted in a 0.9 
year gain in life expectancy when it was compared 
to ACE-inhibitor (10.1 vs. 9.2) and 1 year gain in life
expectancy compared to calcium antagonist (10.1 vs.
9.1). From the payer perspective Tarka was a cost saving
versus ACE-inhibitors and calcium antagonists over the
ﬁve years and the life-time horizon and consequently
Tarka is dominant over usual care. CONCLUSION: The
results showed that the favourable clinical beneﬁt of
Tarka results in positive short and long-term health eco-
nomic beneﬁts.
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OBJECTIVES: A modeling study was performed, com-
bining available efﬁcacy data and costs of complications
to obtain projections of the long-term clinical outcomes
and costs for treatment of type 2 diabetic patients 
using different oral antidiabetic treatment regimens.
METHODS: Baseline data were taken from a double-
blind, multicenter, randomized, parallel group study in
type 2 diabetic patients treated with repaglinide plus
rosiglitazone or rosiglitazone alone. Patients were previ-
ously treated with metformin or a sulfonylurea. The base-
line cohort of patients was on average 57.5 years old,
with a mean A1c level of 9.1%. A Monte Carlo simula-
tion was used to project development of diabetic compli-
cations and associated costs (US Medicare perspective)
over a 30-year period. Risks of macro- and microvascu-
lar complications (derived from published literature) were
combined with hazard ratios for incidence of each com-
plication, to calculate long-term clinical outcomes and
lifetime costs (discounted at 3%). Lifetime costs were 
calculated as pharmacy plus complication costs. After
dose adjustments to achieve glycemic targets, median ﬁnal
daily doses were 6mg repaglinide and 4mg rosiglitazone
for combination therapy and 8mg in rosiglitazone
monotherapy. RESULTS: The reduction of A1c values
from baseline was -1.43% (p < 0.001) and -0.56% (p <
0.001) for combination therapy and rosiglitazone, respec-
tively. The superior A1c reductions of combination
therapy resulted in an increased life expectancy of 0.56
years, while lifetime costs were equal to those of rosigli-
tazone. A lower incidence of cardiovascular events in the
combination therapy was the principal reason for a 
favorable cost effectiveness of combination therapy. 
Consequently, the incremental cost effectiveness ratios
showed that the combination therapy is dominant rela-
tive to rosiglitazone alone. Sensitivity analyses showed the
results were robust. CONCLUSIONS: Incremental cost-
effectiveness ratios showed that a regimen combining
repaglinide and rosiglitazone compares favorably to
rosiglitazone alone, in Type 2 diabetic patients who had
failed metformin or sulfonylurea monotherapy.
